|Mr. Manuel O. Mendez||CEO & Director||10,22M||N/A||1968|
|Mr. Ali Kiboro||Chief Financial Officer||798,9k||N/A||1975|
|Mr. Mohammad El Khoury||Chief Commercial Officer||544,83k||N/A||1960|
|Ms. Vittoria Bonasso||Head of Fin., Group Controller & Principal Accounting Officer||N/A||N/A||1976|
|Dr. Michael Hausmann||Chief Technology Officer||N/A||N/A||N/A|
|Dr. Christine Ginocchio||Chief Scientific & Medical Officer||N/A||N/A||N/A|
|Mr. Christian Albrich||Chief People Officer||N/A||N/A||1964|
|Mr. Esteban Uriarte||Chief Manufacturing Operations Officer||N/A||N/A||N/A|
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
Quotient Limiteds ISS Governance QualityScore, Stand 31. Juli 2022, lautet 6. Die grundlegenden Scores sind Audit: 10, Vorstand: 4, Shareholderrechte: 3, Kompensation: 7.